Healthcare
Over 50 members of Congress are calling on President Donald Trump to direct the National Institutes of Health to issue guidance on when it will exercise so called "march-in rights," effectively canceling exclusivity when patented drugs are not available on reasonable terms. The lawmakers and one consumer advocacy group held up the process as a solution to Trump's promise to bring down drug prices.
Monday, March 28, 2016
Rep. Doggett and Lawmakers to NIH and HHS: Act Now on Drug Affordability
WASHINGTON, March 28 - A group of Senate and House lawmakers led by Reps. Lloyd Doggett (D-Texas) and Peter Welch (D-Vt.), co-chairs of the Prescription Drug Taskforce, as well as Sen. Bernie Sanders (I-Vt.), today urged the Department of Health and Human Services and the National Institutes of Health to step in to lower the cost of a prostate cancer drug, Xtandi, which costs four times more in the United States than in other major countries.
| FOR IMMEDIATE RELEASE March 17, 2016 | Contact: Andrew Braswell (202) 225-4865 |
HHS Urged to Ensure Medicare Beneficiaries Know All Prescription Drug Payment Options